OX40 pathway inhibition and Kaposi sarcoma: An emerging safety signal in atopic dermatitis - PubMed
5 hours ago
- #atopic dermatitis
- #OX40 pathway
- #Kaposi sarcoma
- The article discusses an emerging safety signal linking OX40 pathway inhibition in atopic dermatitis (AD) therapy to Kaposi sarcoma.
- It references recent studies and reviews on OX40 as a therapeutic target in AD and its role in T-cell modulation in cutaneous disorders.
- A phase 2b trial of an anti-OX40 antibody for moderate-to-severe AD is cited, highlighting clinical research in this area.